1
Recently, exome sequencing identified recurrent somatic mutations in SETBP1 in atypical chronic myeloid leukemia (aCML). 2 Of 70 examined patients with aCML, 17 patients (24%) were found to carry mutations in SETBP1. These mutations clustered between codon 858 and 871, all located in the SKI-homologous region of SETBP1. This is a highly conserved region with unknown biological function. In aCML, SETBP1 mutations were associated with worse prognosis and a higher white blood cell count compared with patients with wild-type SETBP1.
2 A search for the presence of SETBP1 mutations in other hematological malignancies closely related to aCML, revealed the presence of SETBP1 mutations in chronic neutrophilic leukemia, chronic myelomonocytic leukemia, unclassified myelodysplastic syndromes/myeloproliferative neoplasms and secondary AML (sAML) evolving from MDS at variable frequencies (4-25%). [2] [3] [4] [5] To evaluate SETBP1 mutations in de novo AML and MDS, we analyzed a total of 944 patients with MDS and AML. This group consisted of 425 de novo AML patients (excluding AML M3) who entered the multicenter treatment trials AML SHG 0199 6 (ClinicalTrials Identifier NCT00209833, June 1999 to September 2004) or AML SHG 0295 7, 8 (February 1995 to May 1999), 326 patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for sAML (n ¼ 170) or primary MDS (n ¼ 156), and 193 primary MDS patients not undergoing intensive therapy or allogeneic HSCT as previously reported. 9 Most samples were from bone marrow. The majority of transplant patients had an unrelated donor (n ¼ 246) compared with 80 patients with a related donor. Standard conditioning was performed in 51 patients, while 275 received reduced intensity conditioning. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Board of Hannover Medical School.
Preparation of mononuclear cells and analysis of prognostic markers were performed as previously reported. 8, 10 The genomic region of the SETBP1 gene, containing codons 858 to 871 with the mutational hotspots D868 and G870 in the SKI-homologous region, was amplified using PCR. Sequences of the primers were: Forward 5 0 -ACCAAAACCCAAAAGGGAAT-3 0 , and reverse 5 0 -CGGTT TTGCAGGCTTTTC-3 0 . Purified PCR fragments were sequenced by Sanger sequencing as previously described. 8, 10 Point mutations were confirmed in an independent experiment. Sequencing analysis was performed with the Mutation Surveyor software (State College, PA, USA). Real-time reverse transcriptase-PCR was performed with patient-derived complementary DNA in MDS patients not undergoing allogeneic HSCT, and for whom RNA and survival information was available using ABL as an endogenous control.
11 SETBP1 expression levels were quantified using the TaqMan Gene Expression Assay (Applied Biosystems, Darmstadt, Germany, Assay ID SETBP1: Hs01098447_m1). Overall survival (OS) and cumulative incidence of non-relapse mortality end points, measured from HSCT, were death (failure) and alive at last followup (censored). The end point for cumulative incidence of relapse (CIR) was relapse after HSCT (failure) and alive at last follow-up or death from non-relapse cause (censored). A Cox proportional hazards model was constructed for multivariate analysis and the two-sided level of significance was set at Po0.05. The statistical analyses were performed with the statistical software package SPSS 20.0 (SPSS Science, Chicago, IL, USA).
In total, we identified 10 patients with mutations in SETBP1. Six of the patients had MDS (frequency 1.7% in MDS), while four of the patients carried the diagnosis of sAML evolving from MDS (frequency 2.4% in sAML evolving from MDS). Eight out of 10 SETBP1 mutated patients underwent allogeneic HSCT for their disease. Interestingly, none of the de novo AML patients was found to carry a mutation in the analyzed region of SETBP1. The SETBP1 mutation was not present in germline DNA obtained from a mutated patient, suggesting somatic origin of the mutation. Mutation type and location are shown in Figure 1a and Table 1 . All mutations were located in the SKI-homologous domain. Patient characteristics are listed in Table 1 . Age (P ¼ 0.95), gender (P ¼ 0.29), WHO classification (P ¼ 0.64) and cytogenetic risk (P ¼ 0.41) were similarly distributed between SETBP1 mutated and wild-type patients. Three SETBP1 mutated patients showed high-risk features such as a complex karyotype or monosomy 7, while four SETBP1 mutated patients showed a more favorable cytogenetic profile, including a normal karyotype or a del 20q (Table 1) . 12 All MDS and sAML patients (n ¼ 519) were also tested for mutations in ASXL1, SRSF2, U2AF1 and SF3B1. Of these, 193 MDS patients who did not undergo allogeneic HSCT were additionally Accepted article preview online 7 May 2013; advance online publication, 21 May 2013 examined for mutations of DNMT3A, ZRSR2, TP53, RUNX1, NRAS, IDH1 and IDH2 as previously described. 9 Out of 10 patients with SETBP1 mutations, 5 patients carried a mutation in SRSF2 (Po0.001; Table 1 ). One SETBP1 mutated patient also showed a mutation in U2AF1, while SETBP1 mutated patients had no mutations in other frequently mutated splicing genes like SF3B1 or ZRSR2. No association was found between ASXL1 and SETBP1 mutations (P ¼ 0.29) in contrast to aCML. 2 In MDS patients, SETBP1
high (n ¼ 66) versus low (n ¼ 65) expression had no impact on OS (Figure 1b) . Furthermore, we found no correlation between SETBP1 expression and SRSF2 (P ¼ 0.97), U2AF1 (P ¼ 0.98), ZRSR2 (P ¼ 0.98) and ASXL1 mutation status (P ¼ 0.22). Interestingly, patients with SF3B1 mutations showed lower SETBP1 expression (P ¼ 0.028). Eight out of 10 SETBP1 mutated patients belonged to the cohort of MDS and sAML (n ¼ 326) who underwent allogeneic HSCT for the treatment of their disease. Thus, in order to evaluate whether Figure 1d ). When considering SRSF2 mutation status in combination with SETBP1 mutation status, we did not find a significant difference in OS (HR 1.02, 95%CI 0.80-1.31, P ¼ 0.86; Figure 1e ). However, a trend towards a higher CIR was found for patients with SETBP1 mutations independent of SRSF2 mutation status (HR 1.30, 95%CI 0.96-1.75, P ¼ 0.087; Figure 1f ). It should be noted that the outcome analysis in our study is limited by the small number of mutated patients. Nevertheless, as in our study, SETBP1 mutations were also associated with a worse prognosis in aCML patients, 2 suggesting that SETBP1 mutations are associated with treatment resistance and/or a more aggressive MDS and sAML subtype. But it is still possible that allogeneic HSCT may abrogate some of the negative effects of SETBP1 mutations.
Our data are highly compelling that SETBP1 mutations have a role in the setting of MDS and sAML, but not in de novo AML. This is in line with previous data showing that the clonal architecture of sAML is different from the clonal architecture of de novo AML. 13 SETBP1 overexpression has been found to promote self-renewal of myeloid progenitors in vivo.
14 SETBP1 expression has also been described to be increased in CML patients with advanced disease/ blast crisis compared with patients with stable disease.
14 In line with these findings, high expression levels of SETBP1 were found to be associated with a poor prognosis in elderly AML patients. 15 The strong association of SETBP1 mutations and mutations in genes of the splicing machinery points to a functional collaboration between these two pathways. Functional studies need to clarify which of the dysregulated functions of SRSF2, like splicing regulation, mRNA export or regulation of translation enhances the oncogenic effect of mutated SETBP1.
In summary, our analysis of 944 patients with AML and MDS suggests that SETBP1 mutations have a role in the setting of MDS and sAML, but not in de novo AML. We found a strong association between SETBP1 mutations and mutations in splicing genes, specifically SRSF2 mutations. In the setting of allogeneic HSCT, we found an independent prognostic impact for a higher CIR. Abbreviations: F, female; M, male; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RAEB-1, refractory anemia with excess blasts-1; RAEB-2, refractory anemia with excess blasts-2; sAML, secondary acute myeloid leukemia; IPSS, International Prognostic Scoring System; int-1, intermediated-1; int-2, intermediated-2; NA, not applicable. Letters to the Editor
